Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00710684 · ClinicalTrials.gov registry record · Phase 2
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 682
- Enrollment target
- 20
- Study locations
NCT00710684 is a Phase 2 study of Alzheimers Disease that has completed, run by GlaxoSmithKline. The registered enrollment target is 682 participants, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00710684, a Phase 2 study of Alzheimers Disease, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 682 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SB-742457 15mg
- DRUG SB-742457 35mg
- DRUG donepezil 5-10mg
Study Locations (20)
Buenos Aires
- GSK Investigational Site - Ciudad Autonoma de Buenos Aires
- GSK Investigational Site - Ciudad Autonoma de Buenos Aires
- GSK Investigational Site - Ciudad de Buenos Aires
- GSK Investigational Site - La Plata
California
- GSK Investigational Site - Fresno
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - San Francisco
Florida
- GSK Investigational Site - Hallandale
- GSK Investigational Site - Hialeah
Arizona
- GSK Investigational Site - Litchfield Park
New Jersey
- GSK Investigational Site - Paterson
New York
- GSK Investigational Site - Syracuse
North Carolina
- GSK Investigational Site - Winston-Salem
Ohio
- GSK Investigational Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2008-07-01 |
| Est. Completion | 2010-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00710684
The ClinicalTrials.gov registry entry for NCT00710684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (83% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00710684 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Buenos Aires, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00710684 about?
NCT00710684 is a clinical study titled "A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease". The study is designed to investigate the safety and efficacy of SB-742457 when added to stable donepezil treatment in subjects with mild-to-moderate Alzheimer's disease.
What is the current status of trial NCT00710684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 682 participants. The study started on 2008-07-01. Estimated completion is 2010-11-16.
What conditions does trial NCT00710684 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00710684?
The interventions under investigation include: Placebo (DRUG), SB-742457 15mg (DRUG), SB-742457 35mg (DRUG), donepezil 5-10mg (DRUG).
Who is sponsoring clinical trial NCT00710684?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00710684 being conducted?
This trial has 20 study locations across Arizona, California, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.